Tropinol esters and related compounds to promote normal processing of APP

Patent metadata

Field	Value
Publication number	US-11325904-B2
Application number	US-201214235405-A
Country	US
Kind code	B2
Filing date	Aug 1, 2012
Priority date	Aug 2, 2011
Publication date	May 10, 2022
Grant date	May 10, 2022

Abstract

In various embodiments, compositions and methods are provided for treatment and/or prevention of amyloidogenic diseases. In certain embodiments, the methods entail administering an effective amount of a tropinol ester to a subject in need thereof for prophylactic or therapeutic effect. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In certain embodiments, methods of reducing the risk, lessening the severity, or delaying the progression or onset of a disease characterized by beta-amyloid deposits in the brain of a mammal are also provided. In certain embodiments, methods of directly or indirectly inhibiting the C-terminal cleavage of APP resulting in the formation of APP-C31 peptide and APPneo (AP-P664) in a mammal are provided.

First claim

What is claimed is:

1. A method of treating Alzheimer's disease in a subject in need thereof with one or more risk factors for Alzheimer's disease, said method comprising:
administering to said subject a compound selected from the group consisting of

or a pharmaceutically acceptable salt, solvate, or hydrate thereof;
wherein said one or more risk factors are selected from the group consisting of a) said subject is a carrier of one or more apolipoprotein E (APOE) ε4 alleles and is AD-P biomarker positive, b) said subject is a carrier of an autosomal dominant mutation in one or more of APP, PS1, or PS2, and c) a combination thereof.

2. The method of claim 1 , wherein said compound is:

3. The method of claim 1 , wherein said compound is:

4. The method of claim 1 , wherein said compound is:

5. The method of claim 1 , wherein said method produces a reduction in the CSF of said mammal of levels of one or more components selected from the group consisting of Tau, phospho-Tau (pTau), APPneo, soluble Aβ40 and soluble Aβ 42 and/or an increase in the CSF of levels of one or more components selected from the group consisting of Aβ42/Aβ40 ratio, Aβ42/Aβ38 ratio, sAPPα, βAPPα/βAPPβ ratio, βAPPα/Aβ40 ratio, and βAPPα/Aβ42 ratio.

6. The method of claim 1 , wherein said method produces an increase in the CSF of said subject of sAPPα.

7. A method of treating Alzheimer's disease in a subject, said method comprising:
administering to the subject an amount of 1-1000 mg of a compound selected from the group consisting of

or a pharmaceutically acceptable salt, solvate, or hydrate thereof.

Assignees

• John Varghese
• Bredesen Dale E
• Buck Inst Res Aging

Inventors

• John Varghese
• Bredesen Dale E

Classifications

• A61K31/444

  containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone · CPC title

• C07D453/02 Primary

  containing not further condensed quinuclidine ring systems · CPC title

• C07D451/12

  acylated by aromatic or heteroaromatic carboxylic acids, e.g. cocaine · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61K31/439

  the ring forming part of a bridged ring system, e.g. quinuclidine (8-azabicyclo [3.2.1] octanes A61K31/46) · CPC title